Human Growth Hormone Market

Rising Incidence of Growth Hormone Deficiency Boosts Market Growth

Cushing's syndrome,turner syndrome, down syndrome, Noonan syndrome, Russell-silver syndrome, Prader Willi syndrome, and others are the most common growth hormone disorders across the globe. For instance, in March 2019, according to the National Organization for Rare Disorders, in the US, turner syndrome affects approximately 1 female in 2,000 to 2,500 live female births and estimated that more than 70,000 women and girls have turner syndrome.

Moreover, growth hormone deficiency is caused by structural pituitary disease or cranial irradiation and occurs in the context of additional features of hypopituitarism.

Early Diagnosis and Awareness Initiatives

Moreover, early diagnosis of endocrine disorders such as Addison’s disease, Cushing’s disease, graves' disease, Hashimoto thyroiditis, hyperthyroidism/hypothyroidism, prolactinoma, and others can substantially improve the chances of successful treatment and prevent severe complications.

The government and various international organizations have launched a number of initiatives to raise awareness about early diagnosis. For instance, The International Coalition of Organizations Supporting Endocrine Patients (ICOSEP), a US-based nonprofit charitable organization, celebrates International Children’s Growth Awareness Day every year to spread awareness about the early diagnosis and treatment of growth hormone deficiency.

The Global Human Growth Hormone Market Industry is projected to experience substantial growth over the next decade. With a market value of 6.9 USD Billion in 2024, it is anticipated to expand to 18.6 USD Billion by 2035. This growth trajectory is indicative of a compound annual growth rate (CAGR) of 9.44% from 2025 to 2035. Such projections highlight the increasing demand for human growth hormone therapies across various demographics, including children with growth disorders and adults seeking anti-aging treatments. The market's expansion reflects broader trends in healthcare and biotechnology, emphasizing the importance of continued research and development in this field.

Technological advancements in biotechnology are significantly influencing the Global Human Growth Hormone Market Industry. Innovations in recombinant DNA technology have enabled the production of synthetic growth hormones that are safer and more effective than their predecessors. These advancements not only enhance the efficacy of treatments but also reduce the risk of side effects, making them more appealing to healthcare providers and patients alike. As a result, the market is expected to grow substantially, with projections indicating a rise to 18.6 USD Billion by 2035. The continuous evolution of biopharmaceuticals is likely to drive further investment and research in this sector.

The rising awareness and education surrounding the benefits of human growth hormone therapy are significantly impacting the Global Human Growth Hormone Market Industry. Healthcare professionals and patients are becoming more informed about the potential advantages of growth hormone treatments, leading to increased demand. Educational initiatives aimed at both practitioners and the public are fostering a better understanding of growth hormone deficiencies and their implications. This heightened awareness is expected to drive market growth, as more individuals seek out therapies that can improve their health outcomes and quality of life.

The establishment of favorable regulatory frameworks and guidelines for the use of human growth hormone is a crucial driver for the Global Human Growth Hormone Market Industry. Regulatory bodies are increasingly recognizing the therapeutic benefits of growth hormone therapy, leading to streamlined approval processes for new treatments. This trend encourages pharmaceutical companies to invest in research and development, ultimately resulting in a wider array of products available in the market. As regulations evolve to support safe and effective use, the market is likely to experience accelerated growth, further solidifying its position in the healthcare landscape.

The growing interest in anti-aging treatments among the aging population is propelling the Global Human Growth Hormone Market Industry. Human growth hormone is often marketed for its potential to improve vitality, muscle mass, and overall well-being in older adults. As the demographic of individuals aged 50 and above expands, there is a corresponding increase in demand for therapies that promote longevity and enhance quality of life. This trend is anticipated to contribute to a compound annual growth rate (CAGR) of 9.44% from 2025 to 2035, reflecting the market's potential to cater to this demographic's needs.

The increasing incidence of growth hormone deficiency among children and adults is a primary driver of the Global Human Growth Hormone Market Industry. This condition, which can lead to stunted growth and other health complications, necessitates effective treatment options. As awareness of growth hormone deficiency grows, more individuals seek medical intervention, thereby expanding the market. In 2024, the market is projected to reach 6.9 USD Billion, reflecting the urgent need for therapies that address this deficiency. The rising prevalence of related disorders, such as Turner syndrome and Prader-Willi syndrome, further underscores the demand for human growth hormone therapies.

By Region, the study segments the market into North America, Europe, Asia-Pacific, and Rest of the World. North America Human Growth Hormone market accounted for USD 1.76 billion in 2021 and is expected to exhibit an 10.02% CAGR during the study period. North America accounted for the largest market share due to the surging availability of novel drugs, backed by the existence of a high number of renowned firms and supportive reimbursement policies.

Moreover, significant government efforts, a well-developed healthcare infrastructure, and a high level of awareness among people is driving the regional market growth during the forecast period.

Further, the major countries studied are: The US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 3: GROWTH HORMONE MARKET SHARE BY REGION 2021 (%)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe growth hormone market accounts for the second-largest market share due to the increased burden of growth hormone deficiencies, the rising availability of artificial growth hormones, and extensive R&D activities. The burden of growth hormone deficiency is rising in Europe due to stress, improper sleep and low glucose levels among people.

For instance, in 2018, according to the European Medicines Agency, growth hormone deficiency affected around 4.7 in 10,000 people in the European Union (EU). Furthermore, the Germany Growth Hormone Market held the largest market share, and the France Growth Hormone Market was the fastest growing market in the Europe region.

The Asia-Pacific Growth Hormone Market is expected to grow at a CAGR of 11.26% from 2024 to 2032. This is due to factors such as penetration of vendors, and a rise in disposable income. Moreover, a surge in drug approvals and the frequent launch of new products also drive market growth.

Moreover, China Growth Hormone Market held the largest market share, and the India Human Human Growth Hormone Market was the fastest growing market in the Asia-Pacific region.

Major market players are spending a lot of money on R&D to increase their product lines, which will help the growth hormone market grow even more. Market participants are also taking a range of strategic initiatives to grow their worldwide footprint, including new product launches, contractual agreements, mergers and acquisitions, increased investments, and collaboration with other organizations.

Competitors in the Human Growth Hormone Market industry must offer cost-effective items to expand and survive in an increasingly competitive and rising market environment.

Novo Nordisk A/S (Denmark) is a Danish pharmaceutical company that discovers, manufactures, and commercializes pharmaceutical products. The company's operating segments are diabetes, hemophilia, growth disorders, obesity, and other biopharmaceuticals. It has a strong clinical pipeline of drugs for type 1 diabetes, type 2 diabetes, obesity, atherosclerosis, hemophilia, and growth disorders.

For instance, in September 2020, the FDA has approved Novo Nordisk's long-acting human growth hormone, Sogroya (Somapacitan). It's the first of the company's regulatory filings for the medicine, also submitted in the EU and Japan, to win approval.

Additionally, Pfizer Inc. (US) is a leading research-based biopharmaceutical company applying science and resources to inventive treatments that extend and significantly improve lives. Pfizer discovers, develops, manufactures, and sells healthcare products worldwide. It operates through two segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

For instance, in February 2020, Pfizer Inc. and OPKO's (US) Once-Weekly NGENLA (somatrogon) injection received marketing authorization by European Union for the treatment of pediatric growth hormone deficiency.